Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University…
<!-- Name:DistributionId Value:8750515 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Cue Biopharma
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE)…
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively…
Cue Biopharma to Present at the Guggenheim I&I Spotlight Series
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively…
Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim…
Early data in the combination study of CUE-101 and KEYTRUDA® (pembrolizumab) supports synergistic activity; of four patients treated in dose escalation in the 2mg/kg and RP2D 4mg/kg…
Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference
CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics…
Cue Biopharma Announces Publication in The Journal of Clinical Investigation…
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to…